🧾 What This Document Is

This is an amended annual report (Form 10-K/A) for AirSculpt Technologies for the year ended December 31, 2025. The company is filing this to correct specific mistakes in its original report. The main error was in how they calculated some non-GAAP financial metrics (like Adjusted EBITDA), not in their core, audited financial statements. Think of it as a "version 2.0" that fixes a math mistake in the appendix, not the main story.

🏢 What The Company Does

In simple terms, AirSculpt is a premium cosmetic surgery company focused on body contouring. They use a proprietary, minimally invasive fat removal technique called AirSculpt® — which they say involves no needles, scalpels, or stitches. Patients are awake during the procedure. They operate 31 centers across the U.S. and Canada, often in upscale areas, and the entire service is paid for out-of-pocket by patients, with no insurance involved.

👉 Why it matters: Their business is entirely dependent on consumer discretionary spending and brand reputation in the elective cosmetic procedure market.

📊 Financial Correction: The Core Issue

This amendment exists to fix errors in the presentation of non-GAAP financial measures. Here’s what went wrong:

Overstatement: A one-time adjustment related to closing their London facility was calculated incorrectly. This made their Adjusted EBITDA and Adjusted Net Income look about $2.6 million better than they actually were for 2025.
Tax Calculation Error: A separate error in calculating the tax effect of adjustments overstated Adjusted Net Income by another $2.7 million.
Net Result: The two errors partially offset each other, leading to a net overstatement of Adjusted Net Income of only $0.1 million.

👉 Why it matters: The company's official, GAAP-compliant financial statements were not wrong. This was a mistake in the supplemental, "adjusted" metrics the company uses to explain its performance. While serious enough to require an amendment, it doesn't indicate fraud or a breakdown in core accounting controls.

💰 2025 Financial & Business Snapshot

Revenue: Approximately $152 million for 2025, down from $180 million in 2024 (a 15.8% decline).
Key Metric: Average revenue per case was $12,809.
Costs: Total advertising costs were $27.3 million. Customer acquisition cost was about $3,114 per patient.
Financing: About 50% of patients used third-party financing (like CareCredit) to pay for procedures.

🚨 Current Challenges & Liquidity Concerns

The filing reveals serious financial pressure:

Debt Covenant Issues: The company has a credit agreement (the "2022 Credit Agreement") and disclosed several "triggering events" — essentially, they are at risk of violating the terms (covenants) of their loan.
Debt Maturity: A portion of their debt was set to mature on June 13, 2025. As a subsequent event, they reported that on March 12, 2026, they entered into an amendment with their lender related to this debt.
Stalled Growth: They state they are "not likely to open new centers in the near term" as they focus on improving liquidity.

👉 Why it matters: This isn't just about fixing a math error. The company is facing real cash flow and debt challenges, which is why they've paused expansion and are working with lenders.

🔮 Strategy & What's Next

Management's plan to turn things around focuses on:

Marketing Optimization: Spending their ad budget more efficiently to get a better return.
Sales Process: Speeding up how quickly a consultation turns into a scheduled procedure.
New Procedures: Introducing new services (like skin tightening) to attract customers.
Financing Options: Expanding patient financing to make procedures more accessible.

👉 The big question: Can these strategies reverse the revenue decline and ease their debt burdens before liquidity becomes a critical issue?

⚖️ Risks & The Bigger Picture

👍 Strengths:

Proprietary, branded procedure (AirSculpt®).
Premium, patient-focused center experience.
Capital-light model; centers can become profitable quickly.

⚠️ Major Risks:

Demand Risk: Procedures are 100% elective and paid by patients. A recession or loss of brand appeal could hurt sales.
Competition: From traditional liposuction, other minimally-invasive tech, and new weight-loss drugs (like Ozempic/Wegovy), which are explicitly mentioned as a competitive threat.
Regulatory/Legal: Their business structure (using Management Services Agreements with physician-owned practices) is complex and could face challenges under "corporate practice of medicine" laws.
Concentration: Nearly all revenue comes from one type of procedure (body contouring).

🧠 The Analogy

Think of AirSculpt like a luxury boutique fitness studio. They have a signature, high-end workout (the AirSculpt® procedure), beautiful locations, and loyal clients. However, they've hit a rough patch: membership is down (revenue decline), they took out a big loan to expand that's coming due (debt covenant issues), and they've had to correct an internal report card (the non-GAAP error). Meanwhile, a trendy new home workout app (weight-loss drugs) is stealing some potential customers. Their survival depends on getting their finances in order and reminding people why their in-person, premium experience is worth the price.

🧩 Final Takeaway

This amendment highlights a correctable accounting mistake, but the real story is AirSculpt's struggle with declining revenue and significant debt pressures. Investors should look past the filing error and focus on whether management's turnaround plan can stabilize the business in a competitive market that now includes powerful pharmaceutical alternatives.

Airsculpt Technologies, Inc. — 10-K/A Filing